z-logo
open-access-imgOpen Access
Melanocyte‐specific CD 8 + T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo
Author(s) -
You S.,
Cho Y.H.,
Byun J.S.,
Shin E.C.
Publication year - 2013
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.12146
Subject(s) - depigmentation , vitiligo , immunology , cd8 , cytotoxic t cell , melanocyte , biology , degranulation , immune system , medicine , dermatology , cancer research , melanoma , in vitro , biochemistry , receptor
Summary In the present study, we established a novel murine model of vitiligo by sequential prime/boost immunizations into the hind footpad and tail dermis with tyrosinase‐related protein 2 ( TRP 2)‐180 ( SVYDFFVWL ) peptide, lipopolysaccharides and cytosine–phosphate–guanosine ( CpG ) oligodeoxynucleotides. Immunized mice developed epidermal depigmentation in the tail skin without hair depigmentation, thereby differentiating this approach from established models of vitiligo. Following intradermal tail immunization, activated CD 8 + interferon ( IFN )‐γ + T cells were recruited locally to the tail skin. In‐vivo cytotoxicity assays demonstrated specific lysis of TRP 2‐180‐presenting cells in immunized mice. Furthermore, the extent of skin depigmentation correlated with the frequency of TRP 2‐180‐specific splenic CD 8 + T cells, as determined by IFN ‐γ and tumour necrosis factor ( TNF )‐α production, and cytotoxic degranulation evidenced by CD 107a staining. These findings suggest a correlation between the presence of TRP 2‐180‐specific CD 8 + effector T cells and the development of depigmented skin lesions in our vitiligo model. This new model of vitiligo, characterized by skin depigmentation without hair depigmentation, is more similar to human disease than previous murine models. Therefore, this model is well suited to future studies on the pathogenesis of vitiligo and the development of novel therapeutics for vitiligo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom